🇺🇸 BNT162b2 (Omi KP.2) in United States

BNT162b2 (Omi KP.2) (bnt162b2-omi-kp-2) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

BNT162b2 (Omi KP.2) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is BNT162b2 (Omi KP.2) approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BNT162b2 (Omi KP.2) in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does BNT162b2 (Omi KP.2) cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.